Tools
Vemurafenib
Indications
The kinase protein family, including MAP, RAS, RAF, MEK, and ERK, has a key role in regulating intracellular and extracellular signaling pathways that control cellular growth, differentiation, transformation, and apoptosis (programmed cell death). In normal cells, these kinases operate in a controlled cascade of phosphorylation and dephosphorylation in response to growth factors, eventually leading to the regulation of cellular growth and proliferation in an organized manner. However, mutations in the genes encoding these kinases can disrupt this regulation, resulting in uncontrolled cell growth, which can lead to the development of cancer.
The rapidly accelerated fibrosarcoma (RAF) family was first identified in 1983 and named for its role in inducing fibrosarcoma in certain mouse models.[1] The RAF family consists of three isoforms—ARAF, BRAF, and CRAF—each encoded by distinct, independent genes. BRAF gained clinical significance in 2002 when mutations in the gene were reported in approximately 66% of malignant melanomas. Subsequent studies found BRAF mutations in up to 80% of cases.[2][3] These mutations were later identified in 40% to 70% of papillary thyroid carcinomas and have also been associated with colorectal cancer, hepatocellular carcinoma, and nearly 100% of hairy cell leukemia cases.[4][5][6] Moreover, BRAF mutations are associated with more aggressive malignant behavior and increased mortality when present in tumor cells.[7]
The most common activating mutation in BRAF is the substitution of glutamic acid for valine at amino acid codon 600 (V600E mutation). A less common variant is the V600K mutation, where lysine is substituted for valine. In clinical practice, several BRAF inhibitors have been approved for the treatment of malignant melanoma with positive BRAF mutations. However, these medications have not shown similar efficacy in other cancers harboring the BRAF mutation. The first BRAF inhibitor approved for clinical use was vemurafenib, followed by dabrafenib and encorafenib.[8]
Indications
Vemurafenib has been approved through the BRIM trials (phases I, II, and III) after demonstrating increased overall survival and progression-free survival in patients with a positive BRAF V600E mutation associated with malignant melanoma. The phase I BRIM trial established the optimal dose of vemurafenib as 960 mg, taken orally twice a day.[9] The phase II BRIM trial reported an overall response rate of 53%, with responses ranging from partial to complete, and a median duration of response of 6.7 months.[10] The phase III BRIM trial, a multicenter randomized controlled trial, compared the efficacy of vemurafenib to dacarbazine, which was the standard treatment for metastatic melanoma at the time.[11]
The study found increased overall survival and progression-free survival in the vemurafenib-treated group compared to the dacarbazine group. However, these results were partially confounded by a crossover during the interim analysis, in which patients from the dacarbazine arm were switched to vemurafenib after early data revealed greater efficacy and response rates with the BRAF inhibitor (vemurafenib). Ultimately, statistical analyses that accounted for the crossover still demonstrated a more favorable response with vemurafenib in patients with stages IIIC and IV melanoma harboring the BRAF V600E mutation. These findings led to the approval of the drug by the US Food and Drug Administration (FDA) in August 2011. The American Society of Clinical Oncology recommends vemurafenib in combination with cobimetinib for patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Alternative treatment options include combination immunotherapy with nivolumab and ipilimumab.[12]
FDA-Approved Indications
Vemurafenib has received FDA approval for the treatment of specific conditions characterized by the presence of BRAF V600 mutations. These include:
- Metastatic and unresectable melanoma with a BRAF V600 mutation [13]
- Erdheim-Chester disease, a rare non-Langerhans histiocytic disorder [14][15]
Off-Label Uses
In addition to its FDA-approved indications, vemurafenib has been used off-label in the treatment of several other BRAF-mutated malignancies, including:
- Metastatic and unresectable melanoma with BRAF V600K mutation [16]
- Refractory non-small cell lung carcinoma BRAF V600 mutation [17]
- BRAF V600E-positive refractory metastatic or unresectable papillary thyroid cancer [18]
- Refractory hairy cell leukemia [19][20]
Mechanism of Action
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism of Action
Vemurafenib is a potent and highly selective inhibitor of the mutated BRAF V600E kinase. By targeting and inhibiting BRAF kinase activity, vemurafenib disrupts signaling through the mitogen-activated protein kinase (MAPK) pathway, thereby blocking the proliferation of malignant cells that carry this specific mutation. The medication is inactive against wild-type BRAF cells, unlike other drugs such as sorafenib, which can inhibit both wild-type and mutated BRAF.[21]
Interestingly, disease progression has been observed at some point during vemurafenib treatment, which has been attributed to the development of resistance within the MAPK pathway. This resistance prompted further clinical trials, which demonstrated improved efficacy of combination therapy with MEK inhibitors such as trametinib in treating BRAF V600E–positive malignant melanomas. Resistance may be driven by BRAF mutations, BRAF fusions, and alterations in integrins and transforming growth factor beta (TGF-β)–signaling pathways.[22][23][24]
Pharmacokinetics
Absorption: Vemurafenib has a mean oral bioavailability of approximately 64% at steady state. The median time to reach peak plasma concentration (Tmax) is about 3 hours after dosing. Steady-state levels are typically reached between days 15 and 22. When administered with a high-fat meal, the area under the curve (AUC) increases 5-fold, the maximum concentration (Cmax) rises by 2.5 times, and Tmax is delayed by approximately 4 hours.
Distribution: The apparent volume of distribution is approximately 106 liters. Vemurafenib exhibits high plasma protein binding, with about 99% bound primarily to albumin and α1-acid glycoprotein.
Metabolism: Vemurafenib is primarily metabolized by the cytochrome P450 enzymes CYP1A2 and CYP3A4.[25] Metabolites account for approximately 5% of the circulating compounds, whereas the remaining 95% consists of the unchanged parent drug.
Elimination: Approximately 94% of vemurafenib is excreted in the feces, with only about 1% eliminated via the urine. The drug has an apparent clearance of 31 L/d. The median elimination half-life is 57 hours, ranging from 30 to 120 hours.
Administration
Available Dosage Forms and Strengths
Vemurafenib is available in an oral tablet formulation, with a strength of 240 mg per tablet.
Adult Dosage
Baseline electrocardiogram (ECG) should be obtained before initiating vemurafenib therapy. Treatment should not begin if the QTc interval exceeds 500 milliseconds. Based on findings from the BRIM II trial, the effective and well-tolerated dose of vemurafenib is 960 mg taken orally twice daily. The medication reaches peak plasma concentration approximately 3 hours after oral administration. The half-life of vemurafenib ranges from 30 to 120 hours, and steady-state plasma concentrations typically reach within 15 to 22 days. The medication is initiated at a dosage of 960 mg twice daily, with a 12-hour interval between doses. Treatment should be discontinued if melanoma progression occurs or if high-grade toxicity develops.[26]
Specific Patient Populations
Hepatic impairment: Dosage adjustment is not necessary for patients with mild-to-moderate hepatic impairment. However, vemurafenib should be used with caution in patients with severe hepatic impairment due to limited available data. Liver function should be assessed before starting vemurafenib, as there is a potential risk for hepatotoxicity.[25]
Renal impairment: No dosage adjustment is necessary for patients with mild-to-moderate renal impairment. However, due to limited data, vemurafenib should be used with caution in individuals with severe renal impairment.
Pregnancy considerations: Vemurafenib has been shown to cross the placenta.[27] In a rare case report, treatment was associated with severe toxic epidermal necrolysis, resulting in spontaneous early preterm birth. Pregnancy may alter the pharmacokinetics of vemurafenib, potentially increasing active drug levels.[28] Another case reported a pregnant woman aged 25 who was treated with vemurafenib for metastatic melanoma. Although the placenta exhibited no evidence of metastasis, the infant developed supraventricular tachycardia, required a neonatal ICU (NICU) admission, was stabilized on a beta-blocker, and was eventually discharged in stable condition.[29]
Breastfeeding considerations: Clinical data on vemurafenib use while breastfeeding do not exist. As vemurafenib binds to plasma proteins at a rate exceeding 99%, its levels in breast milk are likely to remain low. However, due to its long half-life, the drug could accumulate in the infant. The manufacturer recommends discontinuing breastfeeding during treatment and for at least 2 weeks after the last dose of vemurafenib.[30]
Pediatric Patients: The safety and efficacy of vemurafenib have not been established in pediatric populations.
Older patients: Vemurafenib should be administered according to adult dosage guidelines, with adjustments made based on toxicity and renal or hepatic impairment.
Adverse Effects
The most frequently observed adverse effects associated with vemurafenib are cutaneous in nature. These include, but are not limited to, nonspecific maculopapular eruptions, hyperkeratosis, and photosensitivity, particularly when used in conjunction with radiation therapy.
One of the most significant cutaneous adverse effects of vemurafenib is the development of skin cancers, including squamous cell carcinoma and keratoacanthoma, which occur in up to 30% of cases. Less commonly, patients may develop new primary melanomas.[31] These adverse effects usually develop within weeks of initiating treatment and are usually managed with surgical excision without discontinuing BRAF inhibitor therapy. Additionally, secondary melanomas may arise during treatment due to paradoxical activation of the MAPK pathway. Clinical trials have demonstrated that combining BRAF inhibitors with MEK inhibitors reduces the risk of skin tumors. However, this approach is associated with an increased incidence of other cutaneous adverse effects.[32]
Other reported adverse events include hepatotoxicity, arthralgia, diarrhea, and QT prolongation.[33] Anecdotal reports also suggest the development of Dupuytren’s contracture and acute pancreatitis following the use of vemurafenib.[34][35]
Drug-Drug Interactions
- CYP3A4 inhibitors: Strong CYP3A4 inhibitors can elevate vemurafenib plasma concentrations, potentially increasing the risk of toxicity. Coadministration with potent inhibitors such as ketoconazole or clarithromycin should be avoided.
- CYP3A4 inducers: Strong CYP3A4 inducers, including rifampin, phenytoin, and carbamazepine, can reduce vemurafenib plasma levels, potentially decreasing its effectiveness. These combinations should be avoided. If coadministration is necessary, increasing the vemurafenib dose should be considered, as tolerated.
- CYP1A2 substrates: Vemurafenib increases the exposure of CYP1A2 substrates, such as tizanidine. Concomitant use with CYP1A2 substrates should be avoided when possible. If coadministration is unavoidable, close monitoring is recommended, and a dose reduction of the CYP1A2 substrate should be considered.[36]
- Ipilimumab: Concurrent administration of ipilimumab and vemurafenib has been associated with an increased risk of hepatotoxicity. Coadministration should be avoided.
- Digoxin: Vemurafenib increases exposure to P-glycoprotein (P-gp) substrates, such as digoxin. Concomitant use with P-gp substrates with a narrow therapeutic index should be avoided, or their dose should be reduced if coadministered.[37]
Contraindications
Vemurafenib has no absolute contraindications. The only noted contraindication is hypersensitivity to the drug, which rarely occurs during treatment.[38]
Warning and Precautions
New primary malignancies: Cases of squamous cell carcinoma, keratoacanthoma, and new primary melanoma have been reported with vemurafenib use. A thorough dermatological examination is recommended before initiating therapy and should be repeated periodically during treatment. Close monitoring is also advised for non-cutaneous squamous cell carcinomas and other malignancies linked to RAS activation, particularly in patients with preexisting hematological disorders.
Tumor promotion in BRAF wild-type melanoma: Vemurafenib has been shown to activate MAPK signaling in BRAF wild-type cells, which may accelerate tumor cell proliferation. Therefore, treatment should only be initiated after confirming the presence of the BRAF V600E mutation in tumor specimens.
Dermatological reactions: Severe cutaneous adverse reactions—including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS)—have been reported in patients receiving vemurafenib. Immediate discontinuation of the drug is warranted if any of these serious dermatologic conditions occur.[39][40]
QT prolongation: Vemurafenib should be withheld if the QTc interval exceeds 500 ms. Treatment may be resumed at a reduced dose once the QTc interval is less than or equal to 500 ms. Permanent discontinuation is recommended if QTc is more than 500 ms despite correcting modifiable cardiac risk factors.
Photosensitivity: Vemurafenib may cause mild-to-severe photosensitivity reactions. Patients should be advised to minimize sun exposure, wear protective clothing, and apply broad-spectrum sunscreen with SPF 30 or above. If photosensitivity becomes intolerable, dosage adjustment may be necessary.
Ophthalmologic reactions: Uveitis and blurred vision have been reported in patients receiving vemurafenib.[41]
Embryo-fetal toxicity: Vemurafenib may harm a developing fetus. Women of reproductive age should be advised to use effective contraception during treatment and for at least 2 weeks following the final dose.
Radiation sensitization and radiation recall: Vemurafenib may increase the risk of radiation sensitization or radiation recall reactions, particularly in patients receiving prior, concurrent, or subsequent radiation therapy. Careful monitoring is essential when the drug is administered in combination with or following radiation treatment.[42]
Renal failure: Acute interstitial nephritis and acute tubular necrosis may occur during treatment with vemurafenib. Regular monitoring of serum creatinine is essential to detect any signs of renal failure. Mitochondrial dysfunction has also been observed in association with toxicity.[43][44]
Monitoring
A careful skin examination should be performed after the initiation of therapy to monitor for the development of skin tumors, including squamous cell carcinoma, keratoacanthoma, and melanoma. The American Society of Clinical Oncology advises that all cancer patients undergo screening for hepatitis B virus (HBV) before systemic treatment, utilizing tests for hepatitis B surface antigen (HBsAg), hepatitis B core antibody, and hepatitis B surface antibody. Patients with chronic HBV should begin antiviral therapy during cancer treatment and continue it for at least 12 months after the completion of therapy.
HBV DNA should be monitored at baseline and every 6 months during treatment. After discontinuing antivirals, HBV DNA should be checked monthly for the first 3 months, followed by quarterly monitoring. For patients with a history of HBV and high-risk therapies, antiviral treatment should be continued for 12 months after therapy. In patients receiving low-risk therapies, monitoring should focus on HBsAg. Post-therapy monitoring is generally not required unless reactivation occurs.[45]
Testing
- Liver function should be assessed at baseline and monitored regularly throughout the course of treatment.[25]
- Renal function testing is recommended at baseline and periodically during therapy.
- ECGs should be performed at baseline and regular intervals during treatment.
Toxicity
Signs and Symptoms of Toxicity
Phototoxicity, cutaneous reactions, nephrotoxicity, and cardiotoxicity are known adverse effects associated with vemurafenib. Ongoing monitoring with a 12-lead ECG, renal function tests, and liver function tests is advised throughout treatment. A slit-lamp examination and other ophthalmological diagnostic methods are essential to detect uveitis.[46]
Management of Toxicity
Dosage adjustments of the medication may be required based on the severity of toxic reactions. The standard dosage is 960 mg twice daily, which can be reduced to 720 mg twice daily if toxicity occurs for the first time. If toxicity recurs or if high-grade toxicity develops, further dose reduction to 480 mg twice daily is recommended. Doses lower than this are considered therapeutically inactive.
Enhancing Healthcare Team Outcomes
Vemurafenib is the first BRAF inhibitor approved for the treatment of advanced malignant melanoma. Early data suggest it may extend survival by several months; however, the drug is expensive and associated with several severe adverse effects. Additionally, patients on vemurafenib require regular monitoring of liver and renal function to manage potential toxicity.
Oncologists manage the overall treatment plan for patients receiving vemurafenib. Primary Care Physicians and Advanced Practice Providers (APPs) collaborate to monitor toxicity and adjust treatment as needed, working closely with the oncologist. Oncology nurses and pharmacists play a key role in educating patients on the importance of monitoring their skin for new skin cancers. Regular monitoring of liver and renal function is also essential for these patients. An interprofessional team approach, involving oncologists, physicians, APPs, pharmacists, and nurses, is crucial for optimizing outcomes and minimizing adverse reactions.
References
Rapp UR, Goldsborough MD, Mark GE, Bonner TI, Groffen J, Reynolds FH Jr, Stephenson JR. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proceedings of the National Academy of Sciences of the United States of America. 1983 Jul:80(14):4218-22 [PubMed PMID: 6308607]
Level 3 (low-level) evidenceDavies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature. 2002 Jun 27:417(6892):949-54 [PubMed PMID: 12068308]
Level 3 (low-level) evidenceLee B, Mukhi N, Liu D. Current management and novel agents for malignant melanoma. Journal of hematology & oncology. 2012 Feb 14:5():3. doi: 10.1186/1756-8722-5-3. Epub 2012 Feb 14 [PubMed PMID: 22333219]
Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D. BRAF mutation in papillary thyroid carcinoma. Journal of the National Cancer Institute. 2003 Apr 16:95(8):625-7 [PubMed PMID: 12697856]
Level 2 (mid-level) evidenceHuang T, Zhuge J, Zhang WW. Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. Biomarker research. 2013 Jan 16:1(1):3. doi: 10.1186/2050-7771-1-3. Epub 2013 Jan 16 [PubMed PMID: 24252159]
Ziai J, Hui P. BRAF mutation testing in clinical practice. Expert review of molecular diagnostics. 2012 Mar:12(2):127-38. doi: 10.1586/erm.12.1. Epub [PubMed PMID: 22369373]
Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013 Apr 10:309(14):1493-501. doi: 10.1001/jama.2013.3190. Epub [PubMed PMID: 23571588]
Level 2 (mid-level) evidenceProietti I, Skroza N, Michelini S, Mambrin A, Balduzzi V, Bernardini N, Marchesiello A, Tolino E, Volpe S, Maddalena P, Di Fraia M, Mangino G, Romeo G, Potenza C. BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. Cancers. 2020 Jul 7:12(7):. doi: 10.3390/cancers12071823. Epub 2020 Jul 7 [PubMed PMID: 32645969]
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. The New England journal of medicine. 2010 Aug 26:363(9):809-19. doi: 10.1056/NEJMoa1002011. Epub [PubMed PMID: 20818844]
Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. The New England journal of medicine. 2012 Feb 23:366(8):707-14. doi: 10.1056/NEJMoa1112302. Epub [PubMed PMID: 22356324]
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine. 2011 Jun 30:364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5 [PubMed PMID: 21639808]
Level 1 (high-level) evidenceSeth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, Bollin K, Chacon M, Davis N, Faries MB, Funchain P, Gold JS, Guild S, Gyorki DE, Kaur V, Khushalani NI, Kirkwood JM, McQuade JL, Meyers MO, Provenzano A, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Swami U, Truong TG, Tsai KK, van Akkooi A, Weber J. Systemic Therapy for Melanoma: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Oct 20:41(30):4794-4820. doi: 10.1200/JCO.23.01136. Epub 2023 Aug 14 [PubMed PMID: 37579248]
Jarab AS, Al-Qerem WA, Khdour LM, Mimi YA, Khdour MR. New emerging treatment options for metastatic melanoma: a systematic review and meta-analysis of skin cancer therapies. Archives of dermatological research. 2024 Nov 1:316(10):735. doi: 10.1007/s00403-024-03467-2. Epub 2024 Nov 1 [PubMed PMID: 39485529]
Level 1 (high-level) evidenceHaroche J, Cohen-Aubart F, Emile JF, Maksud P, Drier A, Tolédano D, Barete S, Charlotte F, Cluzel P, Donadieu J, Benameur N, Grenier PA, Besnard S, Ory JP, Lifermann F, Idbaih A, Granel B, Graffin B, Hervier B, Arnaud L, Amoura Z. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Feb 10:33(5):411-8. doi: 10.1200/JCO.2014.57.1950. Epub 2014 Nov 24 [PubMed PMID: 25422482]
Kulkarni AM, Gayam PKR, Aranjani JM. Advances in Understanding and Management of Erdheim-Chester Disease. Life sciences. 2024 Jul 1:348():122692. doi: 10.1016/j.lfs.2024.122692. Epub 2024 May 6 [PubMed PMID: 38710283]
Level 3 (low-level) evidenceForschner A, Niessner H, Bauer J, Bender B, Garbe C, Meier F. Successful treatment with vemurafenib in BRAF V600K-positive cerebral melanoma metastasis. JAMA dermatology. 2013 May:149(5):642-4. doi: 10.1001/jamadermatol.2013.372. Epub [PubMed PMID: 23677116]
Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, Souquet PJ, Smit EF, Groen HJ, Kelly RJ, Cho BC, Socinski MA, Pandite L, Nase C, Ma B, D'Amelio A Jr, Mookerjee B, Curtis CM Jr, Johnson BE. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. The Lancet. Oncology. 2016 May:17(5):642-50. doi: 10.1016/S1470-2045(16)00077-2. Epub 2016 Apr 11 [PubMed PMID: 27080216]
Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. The Lancet. Oncology. 2016 Sep:17(9):1272-82. doi: 10.1016/S1470-2045(16)30166-8. Epub 2016 Jul 23 [PubMed PMID: 27460442]
Level 1 (high-level) evidenceTiacci E, De Carolis L, Simonetti E, Capponi M, Ambrosetti A, Lucia E, Antolino A, Pulsoni A, Ferrari S, Zinzani PL, Ascani S, Perriello VM, Rigacci L, Gaidano G, Della Seta R, Frattarelli N, Falcucci P, Foà R, Visani G, Zaja F, Falini B. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. The New England journal of medicine. 2021 May 13:384(19):1810-1823. doi: 10.1056/NEJMoa2031298. Epub [PubMed PMID: 33979489]
Yiğit Kaya S, Mutlu YG, Malkan ÜY, Mehtap Ö, Keklik Karadağ F, Korkmaz G, Elverdi T, Saydam G, Özet G, Ar MC, Melek E, Maral S, Kaynar L, Sevindik ÖG. Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience. Leukemia research. 2024 May:140():107495. doi: 10.1016/j.leukres.2024.107495. Epub 2024 Mar 29 [PubMed PMID: 38599153]
Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America. 2008 Feb 26:105(8):3041-6. doi: 10.1073/pnas.0711741105. Epub 2008 Feb 19 [PubMed PMID: 18287029]
Level 3 (low-level) evidenceLi Y, Zeng H, Qi C, Tan S, Huang Q, Pu X, Li W, Planchard D, Tian P. Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors. ESMO open. 2024 Oct:9(10):103935. doi: 10.1016/j.esmoop.2024.103935. Epub 2024 Oct 9 [PubMed PMID: 39389004]
Level 2 (mid-level) evidenceLarkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. The New England journal of medicine. 2014 Nov 13:371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29 [PubMed PMID: 25265494]
Level 1 (high-level) evidenceBoz Er AB, Sheldrake HM, Sutherland M. Overcoming Vemurafenib Resistance in Metastatic Melanoma: Targeting Integrins to Improve Treatment Efficacy. International journal of molecular sciences. 2024 Jul 20:25(14):. doi: 10.3390/ijms25147946. Epub 2024 Jul 20 [PubMed PMID: 39063187]
. Vemurafenib. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:(): [PubMed PMID: 31643967]
Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16:468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24 [PubMed PMID: 21107323]
Maleka A, Enblad G, Sjörs G, Lindqvist A, Ullenhag GJ. Treatment of metastatic malignant melanoma with vemurafenib during pregnancy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Apr 10:31(11):e192-3. doi: 10.1200/JCO.2012.45.2870. Epub 2013 Feb 11 [PubMed PMID: 23401457]
de Haan J, van Thienen JV, Casaer M, Hannivoort RA, Van Calsteren K, van Tuyl M, van Gerwen MM, Debeer A, Amant F, Painter RC. Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma. Case reports in oncology. 2018 Jan-Apr:11(1):119-124. doi: 10.1159/000487128. Epub 2018 Feb 15 [PubMed PMID: 29606950]
Level 3 (low-level) evidencePagan M, Jinks H, Sewell M. Treatment of metastatic malignant melanoma during pregnancy with a BRAF kinase inhibitor. Case reports in women's health. 2019 Oct:24():e00142. doi: 10.1016/j.crwh.2019.e00142. Epub 2019 Sep 5 [PubMed PMID: 31700806]
Level 3 (low-level) evidence. Vemurafenib. Drugs and Lactation Database (LactMed®). 2006:(): [PubMed PMID: 29999925]
Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T. Cutaneous side-effects of kinase inhibitors and blocking antibodies. The Lancet. Oncology. 2005 Jul:6(7):491-500 [PubMed PMID: 15992698]
Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, Fernandez-Peñas P. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA dermatology. 2015 Oct:151(10):1103-9. doi: 10.1001/jamadermatol.2015.1745. Epub [PubMed PMID: 26200476]
Porta-Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, Thavendiranathan P. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. Journal of the American Heart Association. 2017 Dec 7:6(12):. doi: 10.1161/JAHA.117.007724. Epub 2017 Dec 7 [PubMed PMID: 29217664]
Level 1 (high-level) evidenceChan SW, Vorobiof DA. Dupuytren's contractures associated with the BRAF inhibitor vemurafenib: a case report. Journal of medical case reports. 2015 Jul 8:9():158. doi: 10.1186/s13256-015-0634-4. Epub 2015 Jul 8 [PubMed PMID: 26152183]
Level 3 (low-level) evidenceChung SY, Shen JG, Ghiuzeli CM. Vemurafenib-induced pancreatitis in a patient with recurrent hairy cell leukaemia. BMJ case reports. 2020 Sep 14:13(9):. doi: 10.1136/bcr-2020-236073. Epub 2020 Sep 14 [PubMed PMID: 32928833]
Level 3 (low-level) evidenceZhang W, McIntyre C, Riehl T, Forbes H, Bertran E, Choi HJ, Lee DH, Lee J. Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAF(V600) Mutation-Positive Malignancies. Clinical pharmacology in drug development. 2020 Jul:9(5):651-658. doi: 10.1002/cpdd.788. Epub 2020 Apr 20 [PubMed PMID: 32311241]
Zhang W, McIntyre C, Kuhn M, Forbes H, Kim TM, Lee J, Demidov L, Colburn D. Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAF(V600) Mutation-Positive Metastatic Malignancy. Journal of clinical pharmacology. 2018 Aug:58(8):1067-1073. doi: 10.1002/jcph.1111. Epub 2018 Apr 12 [PubMed PMID: 29645280]
Rana J, Maloney NJ, Rieger KE, Pugliese SB, Strelo JL, Liu A, Zaba LC, Kwong BY. Drug-induced hypersensitivity syndrome like reaction with angioedema and hypotension associated with BRAF inhibitor use and antecedent immune checkpoint therapy. JAAD case reports. 2021 Jul:13():147-151. doi: 10.1016/j.jdcr.2021.04.033. Epub 2021 May 13 [PubMed PMID: 34195327]
Level 3 (low-level) evidenceChen P, Chen F, Zhou B. Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma. Clinical and experimental dermatology. 2019 Apr:44(3):243-251. doi: 10.1111/ced.13751. Epub 2018 Oct 2 [PubMed PMID: 30280426]
Level 1 (high-level) evidenceFlor D, Pedroso M, Coutinho I, Gonçalo M. Toxic epidermal necrolysis caused by vemurafenib in a metastatic malignant melanoma. BMJ case reports. 2025 Feb 16:18(2):. pii: e263057. doi: 10.1136/bcr-2024-263057. Epub 2025 Feb 16 [PubMed PMID: 39956569]
Level 3 (low-level) evidenceDugauquier A, Awada AH, Motulsky E, Kisma N. INTRAVITREAL METHOTREXATE IN VEMURAFENIB-INDUCED UVEITIS. Retinal cases & brief reports. 2024 Jul 1:18(4):455-458. doi: 10.1097/ICB.0000000000001419. Epub [PubMed PMID: 36977328]
Level 3 (low-level) evidenceConen K, Mosna-Firlejczyk K, Rochlitz C, Wicki A, Itin P, Arnold AW, Gross M, Zimmermann F, Zippelius A. Vemurafenib-induced radiation recall dermatitis: case report and review of the literature. Dermatology (Basel, Switzerland). 2015:230(1):1-4. doi: 10.1159/000365918. Epub 2014 Nov 29 [PubMed PMID: 25472806]
Level 3 (low-level) evidenceSanagawa A, Takase H. Increased Mitochondrial Superoxide Level Is Partially Associated With Vemurafenib-Induced Renal Tubular Toxicity. Basic & clinical pharmacology & toxicology. 2025 Apr:136(4):e70015. doi: 10.1111/bcpt.70015. Epub [PubMed PMID: 40018909]
Wanchoo R, Jhaveri KD, Deray G, Launay-Vacher V. Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network. Clinical kidney journal. 2016 Apr:9(2):245-51. doi: 10.1093/ckj/sfv149. Epub 2016 Jan 18 [PubMed PMID: 26985376]
Level 1 (high-level) evidenceHwang JP, Feld JJ, Hammond SP, Wang SH, Alston-Johnson DE, Cryer DR, Hershman DL, Loehrer AP, Sabichi AL, Symington BE, Terrault N, Wong ML, Somerfield MR, Artz AS. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Nov 1:38(31):3698-3715. doi: 10.1200/JCO.20.01757. Epub 2020 Jul 27 [PubMed PMID: 32716741]
Level 3 (low-level) evidenceLiu X, Solebo AL, Keane PA, Moore DJ, Denniston AK. Instrument-based tests for measuring anterior chamber cells in uveitis: a systematic review protocol. Systematic reviews. 2019 Jan 22:8(1):30. doi: 10.1186/s13643-019-0946-3. Epub 2019 Jan 22 [PubMed PMID: 30670103]
Level 1 (high-level) evidence